When the FDA converts an accelerated approval into a full nod, it’s typically associated with a wider label for the drug at hand. But in the case of Johnson & Johnson’s Balversa, the FDA narrowed the ...

Friday afternoon, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application (sNDA) for Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial ...

New York, USA, March 04, 2025 (GLOBE NEWSWIRE) -- BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight BALVERSA (erdafitinib) has strong market potential in ...

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said. The recent approval of Balversa (erdafitinib) ...

The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer. The Food and Drug Administration (FDA) approved Balversa (erdafitinib) for ...

Targeted therapies that aim at specific genetic biomarkers have been widely adopted in several cancer types, but not in bladder cancer. But a new nod the FDA doled out Friday could change that—and ...

DUBLIN--(BUSINESS WIRE)--The "Balversa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Balversa - Drug Insight, 2019 report provides comprehensive information of the ...

Johnson & Johnson’s (J&J) Balversa (erdafitinib) has been granted approval by the European Commission (EC) to treat a subset of bladder cancer patients. The pan-fibroblast growth factor receptor (FGFR ...

10 urothelial cancer patients in Scotland are anticipated to receive this treatment per year [i] High Wycombe, UK (12 May 2025) – Johnson & Johnson is delighted to announce that BALVERSA® (erdafitinib ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

BEERSE, BELGIUM, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA ® (erdafitinib) ...

Please provide your email address to receive an email when new articles are posted on . The FDA today granted accelerated approval to erdafitinib for the treatment of adults with locally advanced or ...